HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dungan, K. Articles by Buse, J. B. Search for Related Content PubMed Articles by Dungan, K. Articles by Buse, J. B. Related Collections Related Article Social Bookmarking                What's this?

Glucagon-Like Peptide 1-Based Therapies for Type 2 Diabetes: A Focus on Exenatide

IN BRIEF

Therapies based on the incretin hormone glucagon-like peptide 1 are novel treatment options for type 2 diabetes that act through a variety of complementary mechanisms. Exenatide, which will likely become the first application to reach the market, has shown promise in phase III trials in reducing hemoglobin A_1c without causing significant hypoglycemia or weight gain.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related Article:

The Diabetes Pandemic: Looking for the Silver Lining

K.M. Venkat Narayan
Clin. Diabetes 2005 23: 51-52. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				T. Elasy Change as a Constant Clin. Diabetes, April 1, 2008; 26(2): 49 - 50. [Full Text] [PDF]

				D. J. Drucker The evidence for achieving glycemic control with incretin mimetics. The Diabetes Educator, March 1, 2006; 32(2 Suppl): 72S - 81S. [Full Text] [PDF]